OP White Papers - random

  1. Broaden Analysis Of Compound Factors For Predictive Solubility Solutions

    Developed by the FDA, the Biopharmaceutics Classification System helps companies when they file for bioequivalence of dosage forms based on in vitro dissolution testing.

  2. Blinding Clinical Supplies Utilizing Over-Encapsulation
    White Paper: Blinding Clinical Supplies Utilizing Over-Encapsulation
  3. Accelerate Flavivirus Vaccine Production With Modern Tools And Solutions

    This white paper gives an overview of modern tools and solutions, adding flexibility and speed to both upstream and downstream operations in flavivirus vaccine production.

  4. Four Reasons For The Rise In Blister Packaging

    Blister packaging, not long ago considered a less significant segment of the North American pharmaceutical packaging industry, is now outpacing most other industry segments. In 2010, blister represented 17% of the global market and recorded $8.1B in revenue, according to Pharmaceutical Packaging Industry – 2011 Yearbook. GBI Research. By Paul Dupont, Director of Business Development North America, Ropack, Inc.

  5. Microemulsion Capsule Technology To Optimize Drug Delivery
    The basic concept of self-emulsifying drug delivery systems (DDS) is to deliver the drug in solution to the site of absorption or to protect the drug from being substantially metabolized in the gastro-intestinal tract or the gut membrane. Submitted by Capsugel
  6. Over-Encapsulation: Common Questions And Challenges
    White Paper: Over-Encapsulation: Common Questions And Challenges
  7. On Target With Antibody Drug Conjugates

    Few would dispute the fact that pharmaceutical formulation has become increasingly challenging. The difficulties all start with the ingredients used to make finished drugs. As more Active Pharmaceutical Ingredient (API) and excipient manufacturing moves offshore, particularly to India and China, there have been increasing complaints of variable quality and tightening supply. Ingredients have never officially been covered by existing pharmaceutical good manufacturing practices (GMPs), although different countries follow guidelines set by WHO, as well as ICH Q7. By Vijay Shah, Executive Director & Chief Operating Officer of Piramal Enterprises

  8. 3 Decisions That Impact Shipping High-Value Active Packaging Containers

    It is the dead of winter in the northern hemisphere and the height of summer in the southern, with external temperature fluctuations exceeding 50 degrees. Flight delays have added precious days to the transport of your multi-million dollar shipment of blockbuster drug from South East Asia destined for Russia. In France, the roads are closed for days due to a monster snowstorm, with your irreplaceable shipment of investigational drugs stopped somewhere en route between Paris and the clinical trial site. Will all be lost, or can informed choices made before the shipment departs ensure product safety despite unforeseen circumstances?

  9. 7 Things To Know When Selecting An Electronic Lab Notebook

    Electronic lab notebooks (ELNs) are one of the primary scientific informatics solutions for helping scientists design, execute, analyze and report on experiments—but selecting the right ELN can be a challenge.

  10. 5 Reasons External Collaborations Fail In Drug Discovery

    In an effort to accelerate innovation, streamline the R&D process, satisfy healthcare expectations and improve the rate of return, pharmaceutical companies have come to embrace external collaborations and their outsourcing partners as an essential part of their discovery programs. This trend towards externalization is significant with roughly 90% of companies outsourcing some steps of drug discovery, and with half of all drugs now resulting from such partnerships. This white paper, discusses the different types of external collaborations research organizations engage in, the reasons that many of these partnerships fail to meet expectations, and an informatics solutions to overcome these issues.